Using evidence to change antimalarial drug policy in Kenya.
about
Vendor-to-vendor education to improve malaria treatment by private drug outlets in Bungoma District, KenyaTargeting vivax malaria in the Asia Pacific: The Asia Pacific Malaria Elimination Network Vivax Working GroupA genome wide association study of Plasmodium falciparum susceptibility to 22 antimalarial drugs in KenyaTemporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal KenyaChanging Malaria Prevalence on the Kenyan Coast since 1974: Climate, Drugs and Vector ControlGenetically Determined Response to Artemisinin Treatment in Western Kenyan Plasmodium falciparum ParasitesDistribution of the main malaria vectors in KenyaA database of antimalarial drug resistance.Benefits of using multiple first-line therapies against malaria.A retrospective analysis of the change in anti-malarial treatment policy: PeruMalaria treatment policy change in Uganda: what role did evidence play?Hot topic or hot air? Climate change and malaria resurgence in East African highlands.The great failure of malaria control in Africa: a district perspective from Burkina FasoMolecular epidemiology of drug-resistant malaria in western Kenya highlands.Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy changePatterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data.Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study.Changing malaria intervention coverage, transmission and hospitalization in Kenya.Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya.Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience.Factors influencing malaria control policy-making in Kenya, Uganda and Tanzania.Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making.The effect of intermittent preventive treatment on anti-malarial drug resistance spread in areas with population movement.Increasing antimalarial drug resistance in Uganda and revision of the national drug policy.Acquired resistance of malarial parasites against artemisinin-based drugs: social and economic impacts.From chloroquine to artemisinin-based combination therapy: the Sudanese experience.Performance of forecasting, warning and detection of malaria epidemics in the highlands of western Kenya.Malaria treatment policy change and implementation: the case of Uganda.Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study.Antimalarial drug prescribing practice in private and public health facilities in South-east Nigeria: a descriptive study.Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy.The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya.Malaria in Kenya's western highlands.Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemether-lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya.Country planning for health interventions under development: lessons from the malaria vaccine decision-making framework and implications for other new interventions.Chloroquine sensitivity: diminished prevalence of chloroquine-resistant gene marker pfcrt-76 13 years after cessation of chloroquine use in Msambweni, KenyaThe decline in paediatric malaria admissions on the coast of Kenya.The quality of sulfadoxine-pyrimethamine prescriptions, counselling and drug-dispensing practices, for children in KenyaTravel as a risk factor for uncomplicated Plasmodium falciparum malaria in the highlands of western Kenya.From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia.
P2860
Q24801800-2E6A0B74-0053-4ED5-942B-87E2604E7201Q27304660-76E7201B-D6A1-47B6-A841-1D56067D727AQ28031418-074E8D0D-DCBC-47B2-9DBE-F16B9C6CC679Q28125914-A866859B-BC44-4151-8A05-3E6B1F1BFE36Q28548617-840A27E7-9B67-4AB4-9A6B-5D6876FDB522Q28554000-4ADECB0B-BBE7-4842-8EF2-1E01B02B9263Q28748314-34BF270E-6891-46C9-BDB1-E8223C2C6878Q30483123-65B4C357-CA1C-47FF-AB14-A8C96E97F4F0Q30483653-2CCACEDC-A6F8-43B5-B917-7FE5C16CD940Q30487719-F7E46AD2-FC94-4963-BB44-C606DA07A62EQ30586992-F4ED9F04-8165-4109-9ACC-2C19C40D1BFFQ30755190-F88ACF32-3ECE-46AF-8922-C9EAB156C8CDQ33286751-C7415D9B-F5EF-48BB-8925-4BAECEF77D81Q33356795-8462AFAD-E90E-4259-ACD1-CE4B8CD91FA3Q33726272-B0002D3E-CA2E-499B-B762-4C51B4D3AF94Q33893267-A28271ED-A17D-45BE-B902-B988CC678ACBQ34055721-A611A32C-786A-4671-B835-F1D4BBDA8BA1Q34273825-DF12E6FB-9415-4EF8-AD4C-1DCF933293A2Q34405184-60E9793E-94D2-43F1-A82B-612B4910BA39Q34434822-418D1988-345F-432F-B2E4-CDAE2770FD54Q34598095-898C1E38-9192-4FD6-8B28-23E7381B3CB5Q34818480-5FDB2607-9E19-4E32-A4BD-D42B124449D2Q34894294-5A0E4045-2FBB-4539-B701-728A7E71D6C9Q35013414-F317CF57-472E-4F9E-BF4F-8BA62038073DQ35026586-5324532A-5487-40A4-9313-B6E2151F83E5Q35065971-72AA24B2-6102-494D-B1D4-DFC8C7112133Q35215133-23C4E6FC-4079-4D4D-A3E8-97539ABD9BE0Q35692263-A27BAE3D-CB1C-437C-96AC-A386AA3135DFQ35699632-FF9D638D-5502-4425-A1B8-BDF9A510B7A2Q35790648-9409FF5A-134E-418C-891E-0BF7DEAE0D76Q35838600-6F2BC208-B482-441F-9E32-27D0CDD9DD28Q35842358-3E6EFFFD-805C-4BFF-95AD-80E280C0A0A6Q35847394-E551200D-1101-4AD2-A90C-D3935E9E6605Q35849636-AEDC28BD-1D09-405B-9DD3-2FF83D5AF235Q35895279-5C244F11-C83F-4619-8689-B78892DC27C4Q35987110-C62C167A-82AC-4528-9580-E27E8F868468Q36372814-116A0722-14F8-4D76-BB90-6C7EB6F467E1Q36463322-5B56D6C1-B938-4F34-A281-13475DD31D1AQ36463333-AEA8BF7C-B367-4E31-9972-BF5D410B26C2Q36471166-523D9787-D207-41B1-A484-129AACB0F90B
P2860
Using evidence to change antimalarial drug policy in Kenya.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Using evidence to change antimalarial drug policy in Kenya.
@ast
Using evidence to change antimalarial drug policy in Kenya.
@en
Using evidence to change antimalarial drug policy in Kenya.
@nl
type
label
Using evidence to change antimalarial drug policy in Kenya.
@ast
Using evidence to change antimalarial drug policy in Kenya.
@en
Using evidence to change antimalarial drug policy in Kenya.
@nl
prefLabel
Using evidence to change antimalarial drug policy in Kenya.
@ast
Using evidence to change antimalarial drug policy in Kenya.
@en
Using evidence to change antimalarial drug policy in Kenya.
@nl
P2093
P2860
P1476
Using evidence to change antimalarial drug policy in Kenya.
@en
P2093
P2860
P304
P356
10.1046/J.1365-3156.2000.00643.X
P577
2000-11-01T00:00:00Z